Irsogladine是一种抗胃溃疡剂,通过M1 muscarininc乙酰胆碱受体结合,有利于细胞间隙连接通讯。
Irsogladine is an anti-gastric ulcer agent that facilitates gap-junctional intercellular communication through M1 muscarininc acetylcholine receptor binding.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Wakana Onuma,et al.Irsogladine maleate, a gastric mucosal protectant, suppresses intestinal polyp development in Apc-mutant mice. Oncotarget. 2016 Feb 23; 7(8): 8640–8652. Published online 2016 Jan 30. doi: 10.18632/oncotarget.7082.
[2] Xin Zhang,et al. Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats. World J Gastroenterol. 2008 Aug 14; 14(30): 4784–4790. Published online 2008 Aug 14. doi: 10.3748/wjg.14.4784.
[3] J Yao,et al. Irsogladine maleate potentiates the effects of nitric oxide on activation of cAMP signalling pathways and suppression of mesangial cell mitogenesis. Br J Pharmacol. 2007 Jun; 151(4): 457–466. Published online 2007 Apr 16. doi: 10.1038/sj.bjp.0707255.
分子式 C9H7Cl2N5 |
分子量 256.09 |
CAS号 57381-26-7 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 2 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT02581696 | Peptic Ulcer | Drug: Lafutidine|Drug: Irsogladine maleate | Boryung Pharmaceutical Co., Ltd|The Catholic University of Korea | Phase 1 | 2015-08-01 | 2017-02-03 |
NCT02759224 | Gastric Ulcer | Drug: BRI-1501|Drug: Lafutidine|Drug: Irsogladine maleate | Boryung Pharmaceutical Co., Ltd | Phase 1 | 2016-04-15 | 2017-02-06 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们